Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399562 | 0.85 | SIRT6 (0.64) | SIRT6LMNAPOLBMAPTCRBN | |
| SCHEMBL29310298 | 0.81 | SIRT6 (0.51) | SIRT6LMNAPOLBMAPTCRBN | |
| SCHEMBL29580457 | 0.79 | MEN1 (0.53) | SIRT6LMNAPOLBMAPTCRBN | |
| SCHEMBL29520409 | 0.79 | ALDH1A1 (0.57) | LMNAPOLBMAPTALDH1A1MEN1 | |
| SCHEMBL22466224 | 0.78 | SIRT6 (0.58) | SIRT6LMNAPOLBMAPTCRBN | |
| SCHEMBL16206797 | 0.78 | SIRT6 (0.59) | SIRT6LMNAPOLBMAPTCRBN | |
| SCHEMBL19003706 | 0.78 | ADRB1 (0.43) | LMNAPOLBMAPTALDH1A1ADRB1 | |
| SCHEMBL7986410 | 0.77 | SIRT6 (0.66) | SIRT6LMNAPOLBMAPTCRBN | |
| SCHEMBL16195957 | 0.77 | MAPT (0.60) | SIRT6LMNAPOLBMAPTCRBN | |
| SCHEMBL15271381 | 0.77 | SIRT6 (0.81) | SIRT6LMNAPOLBMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118891261-A | Covalent EGFR inhibitors and methods of use thereof | 丹娜-法伯癌症研究院 | 2024-11-01 | — | — | CN | disclosed |
| US-20240352021-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-10-24 | — | — | US | disclosed |
| EP-4419529-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023069959-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352021-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | SIRT6 2575/4885LMNA 3596/4885POLB 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.